secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2026-06-08T11:32:53+00:00
Accession:  0001404644-26-000044
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene completes dosing in NGN-401 Rett trial; no HLH, topline expected 2H 2027
--------------------------------------------------------------------------------

- Dosed 25 participants in Embolden trial (target 20, ITT up to 24) due to strong demand from Rett community.
- NGN-401 generally well-tolerated; no HLH cases at 1E15 vg dose across Phase 1/2 and Embolden (n=35).
- Topline data from registrational trial expected in 2H 2027; BLA submission planned.
- Interim Phase 1/2 data with ≥12-month follow-up for all 10 participants expected mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464426000044/0001404644-26-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464426000044/ngne-20260608.htm
  HTML page:      https://secwatch.observer/filing/0001404644-26-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer